Results 91 to 100 of about 46,900 (298)

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

Obesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian   +13 more
wiley   +1 more source

Histochemical localization of cathepsin B, dipeptidyl peptidase I, and dipeptidyl peptidase II in rat bone.

, 1986
The histochemical distribution of the thiol proteases cathepsin B and dipeptidyl peptidase I and the serine protease dipeptidyl peptidase II was examined in rat bone and joint using amino acid derivatives of 4-methoxy-2-naphthylamine (MNA).
D F McDonald, B H Schofield, P L Sannes
core   +1 more source

PERsonalised Medicine for Intensification of Treatment (PERMIT) in type 2 diabetes mellitus: a target trial emulation from routine data

Health Technology Assessment
Background Evidence is required on the relative effectiveness of sulphonylureas, dipeptidyl peptidase-4 inhibitors or sodium–glucose cotransporter 2 inhibitors added to metformin for people with type 2 diabetes mellitus.
David G Lugo-Palacios, Patrick Bidulka, Paul Charlton, Bill Huston, Anna Carnegie, Orlagh Carroll, Stephen O’Neill, Amanda I Adler, Anirban Basu, Richard J Silverwood, Andrew H Briggs, Liam Smeeth, Ian J Douglas, Kamlesh Khunti, Richard Grieve   +14 more
doaj   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

Objective sleep parameters and diurnal blood pressure in concurrent hypertension and type 2 diabetes

Sleep Research, EarlyView.
Abstract Background Hypertension is a primary cardiovascular complication in type 2 diabetes associated with increased morbidity and mortality. Ambulatory blood pressure monitoring (ABPM) is essential for capturing circadian BP variation, which is closely influenced by sleep. Methods Twenty patients (63.75 ± 4.44 years old, 40% female, duration of T2D:
Yan Zhao, Yuzhe Zha, Yuchan Zheng, Lijun Wei, Baoyi Chen, Zefan Zhang, Xiao Tan   +6 more
wiley   +1 more source

Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors

, 2011
Preclinical and clinical studies suggest that whey proteins can reduce postprandial glucose levels and stimulate insulin release in healthy subjects and in subjects with type 2 diabetes by reducing dipeptidyl peptidase-4 (DPP-4) activity in the ...
CAROLI, Anna Maria, COCCHI, Daniela, A. M. Caroli, Giovanni Tulipano, Valeria Sibilia, Sibilia V., TULIPANO, Giovanni, Anna Maria Caroli, G. Tulipano, D. Cocchi, Daniela Cocchi, V. Sibilia   +11 more
core   +1 more source

An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin

Journal of Medical Case Reports, 2018
Background Numerous patients develop diabetes in response to glucocorticoid therapy. This study explored the efficacy, safety, and preventive potential of the dipeptidyl peptidase-4 inhibitor, linagliptin (TRADJENTA®), in the development of ...
Yoshia Miyawaki, Ken-Ei Sada, Yosuke Asano, Keigo Hayashi, Yuriko Yamamura, Sumie Hiramatsu, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Yoshinori Matsumoto, Katsue Sunahori-Watanabe, Tomoko Kawabata, Jun Wada   +12 more
doaj   +1 more source

Staging concept for aging management: Definition, mechanism, and coping strategies

VIEW, EarlyView.
We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang, Shixian Liu, Shangyu Du, Xiangran Cui, Bo Chao, Minglei Liu, Minfei Wu   +6 more
wiley   +1 more source

Characteristics of new users of dipeptidyl peptidase-4 inhibitors and biguanides.

, 2018
Characteristics of new users of dipeptidyl peptidase-4 inhibitors and biguanides.
Ian C. K. Wong (306894), Kenneth K. C. Man (6078836), Paul Stang (3414047), Yea-Huei Kao Yang (528537), Yukari Kamijima (5721233), Kiyoshi Kubota (561420), Patrick Ryan (532054), Chien-Chou Su (6078839), Soko Setoguchi (427043), Shinya Kimura (247648), Edward Chia-Cheng Lai (528535), Martijn Schuemie (505609), Yinghong Zhang (6078842)   +12 more
core   +1 more source

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication

Clinical Case Reports, 2020
We experienced two cases of dipeptidyl peptidase‐4 (DPP‐4) inhibitor‐associated bullous pemphigoid (BP) showing an unfavorable course despite its discontinuation.
Yasutake Shinohara, Toshie Iijima, Shintaro Sakurai, Teruo Jojima, Eriko Ohira, Shujiro Hayashi, Isao Usui, Ken Igawa, Yoshimasa Aso   +8 more
doaj   +1 more source